- Home
- TRMK vs DNLI Comparison
TRMK vs DNLI Comparison
Compare TRMK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMK
- DNLI
- Stock Information
- Founded
- TRMK 1889
- DNLI 2013
- Country
- TRMK United States
- DNLI United States
- Employees
- TRMK N/A
- DNLI 486
- Industry
- TRMK Major Banks
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRMK Finance
- DNLI Health Care
- Exchange
- TRMK Nasdaq
- DNLI Nasdaq
- Market Cap
- TRMK 2.3B
- DNLI 2.4B
- IPO Year
- TRMK 1987
- DNLI 2017
- Fundamental
- Price
- TRMK $37.22
- DNLI $16.28
- Analyst Decision
- TRMK Buy
- DNLI Strong Buy
- Analyst Count
- TRMK 3
- DNLI 14
- Target Price
- TRMK $42.67
- DNLI $33.50
- AVG Volume (30 Days)
- TRMK 290.8K
- DNLI 1.6M
- Earning Date
- TRMK 10-28-2025
- DNLI 11-03-2025
- Dividend Yield
- TRMK 2.58%
- DNLI N/A
- EPS Growth
- TRMK 10.79
- DNLI N/A
- EPS
- TRMK 3.66
- DNLI N/A
- Revenue
- TRMK $766,679,000.00
- DNLI N/A
- Revenue This Year
- TRMK $58.90
- DNLI N/A
- Revenue Next Year
- TRMK $4.37
- DNLI $94,232.03
- P/E Ratio
- TRMK $10.17
- DNLI N/A
- Revenue Growth
- TRMK 37.99
- DNLI N/A
- 52 Week Low
- TRMK $29.77
- DNLI $10.57
- 52 Week High
- TRMK $41.34
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- TRMK 39.88
- DNLI 55.19
- Support Level
- TRMK $37.53
- DNLI $15.53
- Resistance Level
- TRMK $38.98
- DNLI $17.02
- Average True Range (ATR)
- TRMK 0.97
- DNLI 0.85
- MACD
- TRMK -0.07
- DNLI -0.04
- Stochastic Oscillator
- TRMK 25.96
- DNLI 61.08
About TRMK Trustmark Corporation
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.